PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital, a prominent European Venture Capital firm specializing in Life sciences.

​PK MED specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants. Their expertise spans across critical healthcare domains, focusing on local drug delivery systems for rheumatology (PKM-01) and enhancing cell-homing techniques to improve bone marrow transplantation outcomes (PKM-02).

Lead product candidate PKM-01 is developed to treat gout, an excruciating and increasingly prevalent form of arthritis. Today, approved products take time to partially alleviate pain and come with real safety risks.
PKM-01 is a drug combination product (sustained release formulation of the anti-inflammatory drug, colchicine, and an anesthetic) to be injected in the effected joint. PKM-01 is designed to be a new treatment paradigm in gout flares – a safe and very effective pain killer providing relief within minutes.

–  Therapeutic areas: Rheumatology, Bone marrow transplantation

–  Based in: Headquarter : Paris (FRANCE) R&D : Lyon (FRANCE)

–  Employees: 1-10

–  Created in: 2019